Portal de Periódicos da CAPES

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally

2011; Elsevier BV; Volume: 52; Issue: 6 Linguagem: Inglês

10.1194/jlr.m013144

1539-7262

Mohamad Navab, Srinivasa T. Reddy, G.M. Anantharamaiah, Satoshi Imaizumi, Greg Hough, Susan Hama, Alan M. Fogelman,

Cholesterol and Lipid Metabolism

To determine if the dose of peptide administered or the plasma level was more important, doses of 0.15, 0.45, 4.5, or 45 mg/kg/day of the peptide D-4F were administered orally or subcutaneously (SQ) to apoliptotein (apo)E null mice. Plasma levels of peptide were ∼1,000-fold higher when administered SQ compared with orally. Regardless of the route of administration, doses of 4.5 and 45 mg/kg significantly reduced plasma serum amyloid A (SAA) levels and the HDL inflammatory index (P < 0.0001); doses of 0.15 or 0.45 mg/kg did not. A dose of 45 mg/kg/day administered to apoE null mice on a Western diet reduced aortic atherosclerosis by ∼50% (P < 0.0009) whether administered orally or SQ and also significantly reduced plasma levels of SAA (P < 0.002) and lysophosphatidic acid (P < 0.0009). Remarkably, for each dose administered, the concentration and amount of peptide in the feces was similar regardless of whether the peptide was administered orally or SQ. We conclude: i) the dose of 4F administered and not the plasma level achieved determines efficacy; ii) the intestine may be a major site of action for the peptide regardless of the route of administration.